Philogen (PHIL) investor relations material

Executive summary

• Expanded clinical pipeline with multiple late- and early-stage oncology programs, including antibody-cytokine fusions, small molecule ligands, and radiopharmaceuticals, targeting various tumor markers.

• Significant progress in pivotal and registration-enabling trials for lead asset Nidlegy in melanoma and non-melanoma skin cancers, with updated 36-month data published, EMA resubmission in July 2026, and ongoing regulatory submissions in Europe and the U.S.

• Fibromun and dodekin programs advancing in soft tissue sarcoma, glioblastoma, and solid tumors, with promising early clinical results and ongoing regulatory engagement.

• Radiopharmaceutical pipeline advancing with partnerships (FAP, ACP3) and in-house development (OncoCAIX), with new clinical entries planned for 2027.

• Major milestones included the resubmission of the EMA application for Nidlegy™, new Milan office opening, and continued clinical progress across the pipeline.

Financial highlights

• Cash and cash equivalents decreased to €5.13 million, but the group maintains a strong liquidity position with €332 million in current financial assets and a net financial position of €325.7 million as of June 30, 2026.

• Revenue declined sharply year-over-year to €4.26 million, down 51% from €8.72 million, mainly due to lower contract manufacturing and partnership activity.

• Operating expenses increased to €27.57 million, up 12% from €24.55 million, driven by higher personnel and R&D costs.

• EBITDA was negative €21.1 million, a deterioration of 52% from negative €13.9 million in H1 2025.

• Dividend of €28.17 million paid in May 2026 and ongoing share buyback program.

Outlook and guidance

• EMA application for Nidlegy™ resubmitted in July 2026 with new clinical data; US Phase III trial ongoing.

• Multiple pivotal and registration-enabling trials expected to complete recruitment by 2028–2029, with new clinical programs launching in 2027.

• Fibromun: planning for new Phase III study in liposarcoma; ongoing glioblastoma trials with results expected in 2027.

• Continued focus on expanding U.S. clinical operations and potential establishment of U.S. headquarters as portfolio grows.

• Continued investment in AI and expansion of R&D capabilities.